These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31049762)

  • 1. Outcomes of infliximab dose escalation in patients with rheumatoid arthritis.
    Cohen SB; Kremer JM; Dandreo KJ; Reed GW; Magner R; Shan Y; Kafka S; DeHoratius RJ; Ellis L; Parenti D
    Clin Rheumatol; 2019 Sep; 38(9):2501-2508. PubMed ID: 31049762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
    Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC
    J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
    Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis.
    Takasugi K; Nishida K; Natsumeda M; Yamashita M; Yamamoto W; Ezawa K
    Mod Rheumatol; 2018 May; 28(3):452-460. PubMed ID: 28828944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
    Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
    J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.
    Curtis JR; Xie F; Kay J; Kallich JD
    Arthritis Res Ther; 2019 Dec; 21(1):285. PubMed ID: 31831064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs.
    Kobayashi D; Ito S; Takai C; Hasegawa E; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Mod Rheumatol; 2018 Jul; 28(4):599-605. PubMed ID: 28972441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry.
    Tesser J; Lin I; Shiff NJ; Chakravarty SD; Schmajuk G; Hammam N; Desai S
    Clin Rheumatol; 2022 Aug; 41(8):2319-2327. PubMed ID: 35312895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
    Rahman MU; Strusberg I; Geusens P; Berman A; Yocum D; Baker D; Wagner C; Han J; Westhovens R
    Ann Rheum Dis; 2007 Sep; 66(9):1233-8. PubMed ID: 17392352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.
    Bray VJ; Broadwell A; Baraf HSB; Black S; Brady BL; Tkacz J; Yarngo L; DeHoratius RJ
    Drugs R D; 2018 Sep; 18(3):211-219. PubMed ID: 30054896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months: posthoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    J Rheumatol; 2015 Apr; 42(4):599-607. PubMed ID: 25684765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.
    Nadkarni A; McMorrow D; Patel C; Fowler R; Smith D
    J Comp Eff Res; 2017 Nov; 6(8):671-682. PubMed ID: 28791875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist.
    Bao J; Yue T; Li T; He DY; Bao YX
    Int J Rheum Dis; 2016 Apr; 19(4):370-6. PubMed ID: 24798350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
    Thorne C; Bensen WG; Choquette D; Chow A; Khraishi M; Atkins CJ; Kelsall JT; Lehman AJ; Shawi M; Khalil H; Nantel F; Rampakakis E; Sampalis JS; Otawa S
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1142-51. PubMed ID: 24470077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
    Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC
    Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.